The Spanish Ministry of Industry and Tourism awarded the grant through its PERTE Chip initiative for the Barcelona-based company. Spain’s PERTE Chip initiative aims to strengthen design and production capabilities for the country’s microelectronics and semiconductor industry.
InBrain plans to use the funds to accelerate its development of brain-computer interface (BCI) technology. The company’s technology integrates intelligent computing and graphene-based materials to decode and modulate real-time brain activity.
Graphene, a two-dimensional material made of a lattice of carbon atoms, is stronger than steel and thinner than a human hair, the company says. It utilizes a combination of electrical and mechanical properties. InBrain says its neural platform enables ultra-high signal resolution, using machine learning software to decode therapy-specific biomarkers. It delivers highly focused, adaptive neuroelectronic therapy that re-balances pathological neural networks.
Future applications of the BCI technology could include neuromodulation for Parkinson’s, stroke rehabilitation, epilepsy and potentially neuropsychiatric disorders.
In 2023, InBrain received FDA breakthrough device designation for its graphene-neural platform as an adjunctive therapy for treating Parkinson’s disease. It kicked off a first-in-human study last fall, then added $50 million in a Series B funding round a month later.
“We are honored to receive this national support as part of Spain’s effort to lead in cutting-edge neurotechnology,” said Carolina Aguilar, CEO and co-founder of InBrain Neuroelectronics. “This grant will enable us to accelerate our mission to develop precision neurotechnologies that can transform the treatment of neurological diseases, while also helping to position Spain at the forefront of deep tech innovation in healthcare.”
Learn more about BCIs and some of the players in the space HERE.
